Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
- PMID: 32105632
- PMCID: PMC7102538
- DOI: 10.1016/S2213-2600(20)30079-5
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study
Erratum in
-
Correction to Lancet Respir Med 2020; published online Feb 21. https://doi.org/10.1016/S2213-2600(20)30079-5.Lancet Respir Med. 2020 Apr;8(4):e26. doi: 10.1016/S2213-2600(20)30103-X. Epub 2020 Feb 28. Lancet Respir Med. 2020. PMID: 32119827 Free PMC article. No abstract available.
Abstract
Background: An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia.
Methods: In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute respiratory distress syndrome (ARDS) and the proportion of patients requiring mechanical ventilation.
Findings: Of 710 patients with SARS-CoV-2 pneumonia, 52 critically ill adult patients were included. The mean age of the 52 patients was 59·7 (SD 13·3) years, 35 (67%) were men, 21 (40%) had chronic illness, 51 (98%) had fever. 32 (61·5%) patients had died at 28 days, and the median duration from admission to the intensive care unit (ICU) to death was 7 (IQR 3-11) days for non-survivors. Compared with survivors, non-survivors were older (64·6 years [11·2] vs 51·9 years [12·9]), more likely to develop ARDS (26 [81%] patients vs 9 [45%] patients), and more likely to receive mechanical ventilation (30 [94%] patients vs 7 [35%] patients), either invasively or non-invasively. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax. 37 (71%) patients required mechanical ventilation. Hospital-acquired infection occurred in seven (13·5%) patients.
Interpretation: The mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivors is likely to be within 1-2 weeks after ICU admission. Older patients (>65 years) with comorbidities and ARDS are at increased risk of death. The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced.
Funding: None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures


Comment in
-
Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China.Anaesth Crit Care Pain Med. 2020 Apr;39(2):167-169. doi: 10.1016/j.accpm.2020.03.001. Epub 2020 Mar 3. Anaesth Crit Care Pain Med. 2020. PMID: 32142972 Free PMC article. No abstract available.
-
Respiratory support for patients with COVID-19 infection.Lancet Respir Med. 2020 Apr;8(4):e18. doi: 10.1016/S2213-2600(20)30110-7. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145829 Free PMC article. No abstract available.
-
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. Lancet Respir Med. 2020. PMID: 32171062 Free PMC article. No abstract available.
-
COVID-19, ECMO, and lymphopenia: a word of caution.Lancet Respir Med. 2020 Apr;8(4):e24. doi: 10.1016/S2213-2600(20)30119-3. Epub 2020 Mar 13. Lancet Respir Med. 2020. PMID: 32178774 Free PMC article. No abstract available.
-
End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV.JACC Heart Fail. 2020 Jun;8(6):515-517. doi: 10.1016/j.jchf.2020.04.001. Epub 2020 Apr 7. JACC Heart Fail. 2020. PMID: 32265149 Free PMC article. No abstract available.
-
Coronavirus disease 2019 outbreak: is liver disease a prognostic tool?Panminerva Med. 2021 Dec;63(4):553-554. doi: 10.23736/S0031-0808.20.03947-6. Epub 2020 May 14. Panminerva Med. 2021. PMID: 32414233 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous